Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Imaging Height on Diagnostic Accuracy of the "Too Many Toes" Sign in Flatfoot.

Progress in rehabilitation medicine·2026
Same author

Diagnostic potential of urinary <i>PENK</i> methylation for bladder cancer in patients with hematuria: insights from a prospective and multi-institutional study.

Translational andrology and urology·2026
Same author

Vibegron for Anticholinergic-Resistant Pediatric Neurogenic Lower Urinary Tract Dysfunction After Spinal Cord Amputation: A Case Report.

IJU case reports·2026
Same author

Biobased High-<i>T</i><sub>g</sub> Aliphatic Polyethers via the Ring-Opening Polymerization of Dihydrolevoglucosenone-Derived Spiro-Epoxides.

ACS macro letters·2026
Same author

Temperature- and Molecular Weight-Dependent Characteristics of Physisorption of Cyclic Poly(ethylene glycol) on Gold Surfaces.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Accessing Frank-Kasper Phases via Blending of Architecturally Distinct and Sustainable Sugar-Based Block Co-Oligomers.

Macromolecules·2026

Related Experiment Video

Updated: Jun 24, 2026

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Defining Favorable Prognosis in Bone Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor

Dai Koguchi1, Hideyasu Tsumura1, Ken-Ichi Tabata2

  • 1Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.

The Prostate
|March 3, 2026
PubMed
Summary

A new risk model identifies metastatic hormone-sensitive prostate cancer patients who benefit from ARSI therapy. The model, using bone metastasis count, Gleason score, and T stage, refines treatment selection beyond current criteria.

Keywords:
bone metastasisprostate cancerrisk stratification modeltreatment

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Oncology
  • Urology
  • Medical Science

Background:

  • Metastatic hormone-sensitive prostate cancer (mHSPC) with bone metastasis (BM) requires precise treatment selection.
  • Androgen receptor signaling inhibitor (ARSI) therapy offers a promising treatment avenue.
  • Identifying patients most likely to benefit from ARSI therapy is crucial for optimizing outcomes.

Purpose of the Study:

  • To develop and validate a risk stratification model for mHSPC patients with BM.
  • To identify key prognostic factors, including bone metastasis (BM) number, for treatment selection.
  • To compare the efficacy of the developed risk model with existing criteria, such as CHAARTED.

Main Methods:

  • Retrospective analysis of 244 mHSPC patients treated with ARSI plus androgen deprivation therapy.
  • Assessment of prognostic thresholds for BM number using multiple cutoffs (≥4, ≥6, ≥11, ≥21).
  • Construction of a multivariable Cox model incorporating independent prognostic factors (≥11 BM, ≥Gleason score 9, ≥cT3b) to create a risk stratification model.

Main Results:

  • ≥11 bone metastases (BM) demonstrated the strongest prognostic effect for castration resistance-free survival (CRFS) and overall survival (OS).
  • Independent adverse prognostic factors identified were ≥11 BM, ≥Gleason score (GS) 9, and ≥cT3b.
  • The developed risk model classified patients into favorable, intermediate, and poor-risk groups with significantly different CRFS and OS outcomes (p < 0.001).
  • The favorable-risk group in the new model was larger than the low-volume disease group by CHAARTED criteria (39.3% vs. 26.6%), with comparable CRFS and OS.

Conclusions:

  • Patients without ≥11 BM, ≥GS9, and ≥cT3b are likely to benefit from ARSI plus androgen deprivation therapy for mHSPC.
  • The novel risk model identifies a larger favorable-risk subgroup compared to the CHAARTED criteria.
  • This enhanced risk stratification has the potential to improve clinical precision in selecting patients for ARSI therapy.